Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors

PART 1: Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice

Learning objectives

  • Understand current guidelines and utilisation of SGLT2i
  • Describe the potential mechanism of benefit of SGLT2i
  • Initiate and manage SGLT2i in appropriate patients

 


Programme Outline
  • PART 1: Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing PracticeJaved ButlerShelley Zieroth
  • PART 2: SGLT2i are Cardiovascular DrugsJaved Butler
  • PART 3: Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?Stefan Anker
  • PART 4: Case DiscussionJaved ButlerShelley ZierothStefan Anker
  • PART 5: A Follow-up Discussion to the ESC 2020 SessionJaved ButlerShelley Zieroth
This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

PART 2: SGLT2i are Cardiovascular Drugs